Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Open-labelled, Multi-centre Trial Comparing the Safety and Efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r [ritonavir]) to That of Prezista (Darunavir, DRV/r) in Three-class (NRTI [nucleoside RT inhibitors], NNRTI, and PI [protease inhibitor]) Treatment-experienced Patients With Resistance to More Than One PI. POTENT: PrOspecTive EvaluatioN of Tipranavir vs. Darunavir in Treatment Experienced Patients

Next Previous
X
Search
Trial Profile

A Prospective, Randomized, Open-labelled, Multi-centre Trial Comparing the Safety and Efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r [ritonavir]) to That of Prezista (Darunavir, DRV/r) in Three-class (NRTI [nucleoside RT inhibitors], NNRTI, and PI [protease inhibitor]) Treatment-experienced Patients With Resistance to More Than One PI. POTENT: PrOspecTive EvaluatioN of Tipranavir vs. Darunavir in Treatment Experienced Patients

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tipranavir (Primary) ; Darunavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms POTENT
  • Sponsors Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 30 Sep 2021 This trial has been completed in France (End Date: 20 Sep 2008), according to European Clinical Trials Database record.
    • 04 Sep 2021 This trial has been completed in Spain, according to European Clinical Trials Database.
    • 23 Oct 2012 Planned number of patients changed from 800 to 1040 as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top